US Edition
Pfizer and Valneva Seek Approval for Lyme Vaccine After Phase 3 Trial
Pfizer and Valneva will seek U.S. approval for a Lyme vaccine showing over 70% efficacy in a late-stage trial despite missing initial statistical goals.
- Pfizer and Valneva announced that their Lyme disease vaccine candidate demonstrated strong efficacy of over 70% in the Phase 3 VALOR trial, though the primary endpoint was not met.
- Despite missing the statistical goal in the trial due to fewer Lyme disease cases than anticipated, Pfizer expressed confidence in the vaccine's potential and plans to seek regulatory approval.
- Lyme disease, caused by bacteria commonly spread by ticks, affects around half a million Americans annually, but there is currently no approved human vaccine available.
55 Articles
55 Articles
MyCentralOregon.com
Doctors say Pfizer's Lyme disease vaccine trial results 'encouraging' after more than 70% efficacy shown
Pfizer logo (Photo Illustration by Nikolas Kokovlis/NurPhoto via Getty Images) (NEW YORK) — Earlier this week, pharmaceutical company Pfizer and its partner Valneva announced that an experimental Lyme disease vaccine showed more than 70% efficacy in late-stage clinical trials. The candidate, PF-07307405, showed 73.2% efficacy in reducing confirmed cases of Lyme disease cases after the fourth and final dose was administered when compared to a pla…
A Pfizer and Valveva pharmaceutical laboratory vaccine against Lyme disease demonstrated "high efficacy" in a clinical trial, without meeting its primary criterion.
Pfizer plans to seek marketing approval for its new Lyme disease vaccine, even though the company's latest clinical trial fell short of its goal. However, the data collected shows that the vaccine reduced infection by more than 70 percent, which is why scientists and drugmakers believe the protection achieved is clinically meaningful.
Pfizer will seek approval for its Lyme disease vaccine
Pfizer said its experimental Lyme disease vaccine was more than 70% efficacious in reducing confirmed cases of the tickborne illness in a phase 3 trial, although the trial missed its primary endpoint. The drugmaker said it will pursue regulatory approval of the vaccine, which it is developing with Valneva. Last year, Valneva said it expected Pfizer to launch the vaccine in U.S. and European
Coverage Details
Bias Distribution
- 66% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
